Absci is a generative AI drug creation company. Our mission is simple: create better biologics for patients, faster.
Most biologics drug discovery approaches today look to existing antibody libraries for incremental improvements. We recently showed how we design de novo antibodies "from scratch" on a computer. Our zero-shot AI approach designs antibodies without prior learning on the specific target, generating candidates unlike those found in existing databases. Our wet lab can experimentally validate the candidates that work right out of the computer - without the slow and costly step of lead optimization. This potentially reduces the time it takes to get new drug leads into the clinic, while unlocking treatments for traditionally "undruggable" diseases and improved therapeutic possibilities for many others.
Historically, biologics drug discovery is risky, time-consuming, and expensive, with a >90% failure rate. Instead of looking for the needle in a haystack, we can create the needle. If we could reduce our preclinical development timelines and increase our success rate, we could dramatically impact patients' lives.
Absci enables a shift from drug discovery to drug creation. We unlock new possibilities in de novo design, lead optimization, target identification, and antibody-drug conjugate (ADC) development, where drugmakers seek candidates with tailored target binding, better manufacturability, lower immunogenicity, and shorter development times. By enabling biologics drug discovery to happen more quickly and efficiently, we help our partners bring drugs to more patients everywhere.
Our Integrated Drug Creation™ platform combines AI with synthetic biology to overcome the limits of traditional biologics drug discovery. We can build and test millions of AI designs every week, and the resulting wet lab data propels an experimental cycle that takes us from designs to data in as little as six weeks. It gives us the data to train, the AI to create, and the wet lab to validate new biologic-based therapeutics.